Literature DB >> 20160037

Inactivation of junctional adhesion molecule-A enhances antitumoral immune response by promoting dendritic cell and T lymphocyte infiltration.

Masato Murakami1, Chiara Francavilla, Ilaria Torselli, Monica Corada, Luigi Maddaluno, Antonio Sica, Gianluca Matteoli, Iliyan Dimitrov Iliev, Alberto Mantovani, Maria Rescigno, Ugo Cavallaro, Elisabetta Dejana.   

Abstract

Junctional adhesion molecule-A (JAM-A)-null dendritic cells (DCs) are more motile and effective than their wild-type counterpart in promoting contact hypersensitivity reaction. Here, we show that the growth and aggressiveness of pancreatic islet cell carcinoma induced by SV40 T antigen expression in beta cells (Rip1Tag2 mice) are significantly reduced in JAM-A-null mice. Because these tumor cells do not express JAM-A, we focused on changes in stroma reactivity. In the absence of JAM-A, tumors showed a small but significant reduction in angiogenesis and a marked increase in the immune reaction with enhanced infiltration of DCs (CD11c+ and MHC-II+) and CD4+ and CD8+ lymphocytes. In contrast, phagocyte number was not affected. DC capacity to produce cytokines was not significantly altered, but transmigration through JAM-A-null endothelial cells was increased as compared with JAM-A-positive endothelium. On adoptive transfer, JAM-A(-/-) DCs were recruited to tumors at slightly but significantly higher rate than JAM-A(+/+) DCs. Ablation of CD4+ and CD8+ cells with specific antibodies abrogated the inhibitory effect of JAM-A deletion on tumor growth and angiogenesis. These findings support the idea that, in the Rip1Tag2 tumor model, abrogation of JAM-A reduces cancer development by increasing antitumor immune response.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20160037     DOI: 10.1158/0008-5472.CAN-09-1703

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  Junctional adhesion molecule A promotes epithelial tight junction assembly to augment lung barrier function.

Authors:  Leslie A Mitchell; Christina Ward; Mike Kwon; Patrick O Mitchell; David A Quintero; Asma Nusrat; Charles A Parkos; Michael Koval
Journal:  Am J Pathol       Date:  2014-11-28       Impact factor: 4.307

2.  Halting the vicious cycle within the multiple myeloma ecosystem: blocking JAM-A on bone marrow endothelial cells restores angiogenic homeostasis and suppresses tumor progression.

Authors:  Antonio G Solimando; Matteo C Da Vià; Patrizia Leone; Paola Borrelli; Giorgio A Croci; Paula Tabares; Andreas Brandl; Giuseppe Di Lernia; Francesco P Bianchi; Silvio Tafuri; Torsten Steinbrunn; Alessandra Balduini; Assunta Melaccio; Simona De Summa; Antonella Argentiero; Hilka Rauert-Wunderlich; Maria A Frassanito; Paolo Ditonno; Erik Henke; Wolfram Klapper; Roberto Ria; Carolina Terragna; Leo Rasche; Andreas Rosenwald; Martin K Kortüm; Michele Cavo; Domenico Ribatti; Vito Racanelli; Hermann Einsele; Angelo Vacca; Andreas Beilhack
Journal:  Haematologica       Date:  2021-07-01       Impact factor: 9.941

3.  Abrogation of junctional adhesion molecule-A expression induces cell apoptosis and reduces breast cancer progression.

Authors:  Masato Murakami; Costanza Giampietro; Monica Giannotta; Monica Corada; Ilaria Torselli; Fabrizio Orsenigo; Andrea Cocito; Giovanni d'Ario; Giovanni Mazzarol; Stefano Confalonieri; Pier Paolo Di Fiore; Elisabetta Dejana
Journal:  PLoS One       Date:  2011-06-17       Impact factor: 3.240

4.  Genomic organisation, embryonic expression and biochemical interactions of the zebrafish junctional adhesion molecule family of receptors.

Authors:  Gareth T Powell; Gavin J Wright
Journal:  PLoS One       Date:  2012-07-18       Impact factor: 3.240

5.  Endothelial cell junctional adhesion molecule C plays a key role in the development of tumors in a murine model of ovarian cancer.

Authors:  David A Leinster; Bartomeu Colom; James R Whiteford; Darren P Ennis; Michelle Lockley; Iain A McNeish; Michel Aurrand-Lions; Triantafyllos Chavakis; Beat A Imhof; Frances R Balkwill; Sussan Nourshargh
Journal:  FASEB J       Date:  2013-07-03       Impact factor: 5.191

Review 6.  The F11 Receptor (F11R)/Junctional Adhesion Molecule-A (JAM-A) (F11R/JAM-A) in cancer progression.

Authors:  Kamila Czubak-Prowizor; Anna Babinska; Maria Swiatkowska
Journal:  Mol Cell Biochem       Date:  2021-09-17       Impact factor: 3.396

Review 7.  The Roles of Junctional Adhesion Molecules (JAMs) in Cell Migration.

Authors:  Junqi Wang; Han Liu
Journal:  Front Cell Dev Biol       Date:  2022-03-09

8.  F11R is a novel monocyte prognostic biomarker for malignant glioma.

Authors:  Winnie W Pong; Jason Walker; Todd Wylie; Vincent Magrini; Jingqin Luo; Ryan J Emnett; Jaebok Choi; Matthew L Cooper; Malachi Griffith; Obi L Griffith; Joshua B Rubin; Gregory N Fuller; David Piwnica-Worms; Xi Feng; Dolores Hambardzumyan; John F DiPersio; Elaine R Mardis; David H Gutmann
Journal:  PLoS One       Date:  2013-10-11       Impact factor: 3.240

Review 9.  Targeting Opposing Immunological Roles of the Junctional Adhesion Molecule-A in Autoimmunity and Cancer.

Authors:  Caio S Bonilha; Robert A Benson; James M Brewer; Paul Garside
Journal:  Front Immunol       Date:  2020-11-25       Impact factor: 8.786

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.